<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>2,2,5,7,8-Pentamethyl-6-hydroxychromane (PMC) is the most potent analogue of <z:chebi fb="0" ids="22470">alpha-tocopherol</z:chebi> for anti-oxidation </plain></SENT>
<SENT sid="1" pm="."><plain>It is more hydrophilic than other <z:chebi fb="0" ids="22470">alpha-tocopherol</z:chebi> derivatives and has potent free radical-scavenging activity </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, PMC significantly attenuated middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO)-induced focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="3" pm="."><plain>Administration of PMC at 20mg/kg, showed marked reductions in <z:mpath ids='MPATH_124'>infarct</z:mpath> size compared with that of control rats </plain></SENT>
<SENT sid="4" pm="."><plain>MCAO-induced focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was associated with increases in HIF-1alpha, active caspase-3, iNOS, and nitrotyrosine expressions in ischemic regions </plain></SENT>
<SENT sid="5" pm="."><plain>These expressions were markedly inhibited by treatment with PMC (20mg/kg) </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, PMC (4-12 microM) inhibited respiratory bursts in human neutrophils stimulated by <z:chebi fb="0" ids="53490">fMLP</z:chebi> (800 nM) and <z:chebi fb="1" ids="53780">PMA</z:chebi> (320 nM) </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, PMC (6, 12, and 60 microM) also significantly inhibited neutrophil migration stimulated by <z:chebi fb="0" ids="25029">leukotriene</z:chebi> B(4) (160 nM) </plain></SENT>
<SENT sid="8" pm="."><plain>An electron spin resonance (ESR) method was conducted on the scavenging activity of PMC on the free radicals formed </plain></SENT>
<SENT sid="9" pm="."><plain>PMC (12 microM) greatly reduced the ESR signal intensities of <z:chebi fb="1" ids="18421">superoxide</z:chebi> <z:chebi fb="5" ids="22563">anion</z:chebi>, <z:chebi fb="1" ids="29191">hydroxyl radical</z:chebi>, and <z:chebi fb="0" ids="29309">methyl radical</z:chebi> formation </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, we demonstrate a potent neuroprotective effect of PMC on MCAO-induced focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in vivo </plain></SENT>
<SENT sid="11" pm="."><plain>This effect may be mediated, at least in part, by inhibition of free radical formation, followed by inhibition of HIF-1alpha activation, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> formation (active caspase-3), neutrophil activation, and <z:mp ids='MP_0001845'>inflammatory responses</z:mp> (i.e., iNOS and nitrotyrosine expressions), resulting in a reduction in the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion brain injury </plain></SENT>
<SENT sid="12" pm="."><plain>Thus, PMC treatment may represent a novel approach to lowering the risk or improving function in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion brain injury-related disorders </plain></SENT>
</text></document>